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CCDC102B confers risk of low vision and blindness
in high myopia
Yoshikatsu Hosoda1,2, Munemitsu Yoshikawa1,2, Masahiro Miyake1,2, Yasuharu Tabara2, Noriaki Shimada3,
Wanting Zhao4, Akio Oishi1, Hideo Nakanishi1, Masayuki Hata1, Tadamichi Akagi1, Sotaro Ooto1,
Natsuko Nagaoka3, Yuxin Fang3, Nagahama Study group, Kyoko Ohno-Matsui3, Ching-Yu Cheng4,5,6,
Seang Mei Saw4,6,7, Ryo Yamada2, Fumihiko Matsuda2, Akitaka Tsujikawa1 & Kenji Yamashiro 1,8
The incidence of high myopia is increasing worldwide with myopic maculopathy, a compli-
cation of myopia, often progressing to blindness. Our two-stage genome-wide association
study of myopic maculopathy identiﬁes a susceptibility locus at rs11873439 in an intron of
CCDC102B (P= 1.77 × 10−12 and Pcorr= 1.61 × 10−10). In contrast, this SNP is not signiﬁcantly
associated with myopia itself. The association between rs11873439 and myopic maculopathy
is further conﬁrmed in 2317 highly myopic patients (P= 2.40 × 10−6 and Pcorr= 1.72 × 10−4).
CCDC102B is strongly expressed in the retinal pigment epithelium and choroids, where
atrophic changes initially occur in myopic maculopathy. The development of myopic macu-
lopathy thus likely exhibits a unique background apart from the development of myopia itself;
elucidation of the roles of CCDC102B in myopic maculopathy development may thus provide
insights into preventive methods for blindness in patients with high myopia.
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The incidence of myopia is rapidly increasing worldwide
1–3.
Although patients with myopia do not usually suffer from
visual disturbance with the aid of glasses or contact lenses,
when the degree of myopia becomes severe and worsens to the
stage of “high myopia”, complications can occur, leading to
reduced vision or blindness. The main vision-threatening com-
plication in high myopia is myopic maculopathy, in which the
retinal pigment epithelium (RPE) and choroid beneath the neural
retina become severely atrophic, resulting in atrophy of the whole
retina and choroid at the macula, the center part of the posterior
pole in the eyeball. Myopic maculopathy is a progressive disease
that constitutes the leading cause of blindness in Japanese indi-
viduals4 and the second-leading cause of low vision in Chinese
individuals5,6. Even though myopia is less prevalent in Cauca-
sians, myopic maculopathy is also a signiﬁcant cause of blindness
in Caucasians7–11.
Eyeball enlargement in highly myopic eyes, particularly axial
length elongation, signiﬁcantly contributes to the development of
myopic maculopathy12,13. However, not all eyes with longer axial
length develop myopic maculopathy, and it cannot be predicted
which eyes will develop myopic maculopathy and blindness. In
addition, eyes without high myopia can also develop fundus
changes associated with myopic maculopathy. Discovery of the
unique background for developing myopic maculopathy distinct
from the background of developing myopia may lead to the
establishment of novel preventive methods for myopic maculo-
pathy and blindness. Conversely, if myopic maculopathy con-
stitutes an unavoidable consequence of myopia progression,
blindness in high myopia could not be prevented by targeting
myopic maculopathy.
Recent genetic studies have revealed genes associated with the
development of myopia and high myopia14,15. As high myopia is
predominant in East Asia, genetic studies on high myopia have
been conducted mainly in this region16–23. However, it remains
unclear whether genetic background affects the development of
vision-threatening complications in highly myopic eyes.
Myopic maculopathy is classiﬁed into ﬁve grades according to
severity; categories 2, 3, and 4 are regarded as the pathological
state, whereas categories 0 and 1 are considered the physiological
state24. In the present study, we aimed to identify genes associated
with vision-threatening complications in high myopia by per-
forming a two-stage genome-wide association study (GWAS)
using myopic maculopathy grade in a Japanese community-based
cohort that included participants with all refractive states; i.e.,
hyperopia, emmetropia, low-grade myopia, and high myopia.
Furthermore, we evaluated associations between the discovered
gene and myopic maculopathy grade using only highly myopic
eyes to conﬁrm that the identiﬁed gene contributed to the
development of myopic maculopathy and subsequent low vision
and blindness in highly myopic eyes. Our ﬁndings provide
important insights into susceptibility genes for the development
of myopic maculopathy distinct from myopia progression.
Results
Two-stage GWAS for myopic maculopathy. The Nagahama
cohort demographics used in this study are shown in Supple-
mentary Table 1. Myopic maculopathy was graded in all fundus
photographs of the participants, and participants with category 0
or 1 in both eyes were used as controls, whereas participants with
category 2, 3, or 4 in at least one eye were used as cases of myopic
maculopathy. We compared genotype distributions between
myopic maculopathy cases and controls using logistic regression
analysis. Age, sex, and axial length were used as covariates for
adjustment. The axial length of the eye with the more severe
grade was chosen, and the longer axial length was used when the
grade was the same in both eyes. Although we did not include
principal components in covariates for the adjustment, an inﬂa-
tion factor (λGC) of 1.025 indicated good control of population
substructure (Supplementary Fig. 1).
During the ﬁrst stage with 4462 participants and using a
Bonferroni correction threshold of 1.06 × 10−8, we identiﬁed a
genome-wide signiﬁcant association at CCDC102B rs11873439 (P
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Fig. 1 Manhattan plot of case-control GWAS on myopic maculopathy. Each plot shows −log10-transformed P values for all SNPs adjusted for age, sex, and
axial length. The horizontal line represents the genome-wide signiﬁcance threshold of 1.06 × 10−8. GWAS, genome-wide association study
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= 1.46 × 10−10 and Pcorr= 4.26 × 10−9, Fig. 1 and Table 1). In the
subsequent replication stage with 3279 participants, the
CCDC102B rs11873439 genotype distribution differed signiﬁ-
cantly between participants with category 0 or 1 and those with
category 2, 3, or 4 (P= 4.20 × 10−4 and Pcorr= 1.58 × 10−3).
Meta-analysis of both stages further conﬁrmed the robust
association of this locus with myopic maculopathy (P= 1.77 ×
10−12 and Pcorr= 1.61 × 10−10).
CCDC102B associates with myopic maculopathy in high
myopia. In the discovery and replication stages of the Nagahama
GWAS analysis, 828 participants exhibited high myopia with an
axial length of more than 26 mm in at least one eye. Within these
highly myopic eyes, CCDC102B rs11873439 showed signiﬁcant
association with myopic maculopathy (P= 2.74 × 10−4 and
Pcorr= 3.58 × 10−3, Table 2).
We further conducted replication analysis on the association
between CCDC102B rs11873439 and myopic maculopathy
development using hospital-based high myopia samples (Supple-
mentary Table 2). We collected DNA from 1158 patients with
high myopia (axial length > 26 mm in at least one eye) at two
facilities in Japan. In this hospital-based analysis of highly myopic
eyes, eyes with myopic choroidal neovascularization (mCNV)
were also included in the case samples because mCNV usually
leads to low vision or blindness. Among this cohort, 190 patients
exhibited category 0 or 1 in both eyes, and 968 patients had
category 2, 3, or 4 myopic maculopathy or mCNV in at least one
eye. The genotype distribution of rs11873439 did not signiﬁcantly
deviate from Hardy–Weinberg equilibrium in either group (P >
0.05). This hospital-based analysis revealed the signiﬁcant
association of rs11873439 with myopic maculopathy in high
myopia (P= 0.0221 and Pcorr= 0.0205), and a meta-analysis of
the 828 highly myopic participants in the Nagahama cohort
further conﬁrmed its signiﬁcant association with myopic
maculopathy (P= 2.70 × 10−5 and Pcorr= 2.03 × 10−4).
We also performed subgroup analysis of these highly myopic
samples categorized by myopic maculopathy grade (Supplemen-
tary Table 3). The effect allele frequency in category 2, 3, and
4 samples was higher than that in category 0 and 1 samples;
however, the effect allele frequency did not go up with myopic
maculopathy grade.
Replication in other ethnicities and meta-analysis. To conﬁrm
the association between CCDC102B rs11873439 and myopic
maculopathy in highly myopic eyes in other ethnicities, we con-
ducted replication analyses using three different cohorts of three
different ethnicities (Table 2). In all three case-control studies
using only highly myopic participants, the minor allele frequency
was greater in cases, and the odds ratios without adjustment were
similar to the Japanese results. The Chinese cohort showed sig-
niﬁcant association between rs11873439 and myopic maculo-
pathy (P= 0.0458) when analyzed without adjustment, although
the analysis results substantially varied in the analysis with cor-
rection for age, sex, and axial length possibly because of the small
sample size. The ﬁxed effect meta-analysis of all ethnicity group
data revealed strong association between rs11873439 and myopic
maculopathy development (P= 2.40 × 10−6 and Pcorr= 1.72 × 10
−4, Table 2).
Association of CCDC102B with axial length. In the entire
Nagahama cohort, the association of rs11873439 with axial length
was also evaluated because the severity of myopic maculopathy
may be associated with longer axial length. Among the 7739
participants, linear regression analysis revealed that
rs11873439 showed a mild, but not statistically signiﬁcant asso-
ciation with axial length (β= 0.038 and P= 0.0782) when
adjusted for age and sex.
Subgroup analysis revealed that the odds ratio of the
association between CCDC102B rs11873439 and myopic maculo-
pathy was similar between axial length of 22–28mm: 1.51 in eyes
with axial length of 22–24mm, 1.44 in eyes with axial length of
24–26 mm, and 1.45 in eyes with axial length of 26–28 mm
(Supplementary Table 4). Although the sample size was small, the
effect of CCDC102B in the extreme myopia group (axial length >
28 mm) was weaker (P= 0.490, odds ratio= 1.29).
Expression of CCDC102B in the human retina and RPE-
choroid. To conﬁrm expression of CCDC102B in the human
retina or RPE-choroid, we conducted SYBR Green quantitative
PCR (qPCR) using cDNA from human retina and RPE-choroid.
Relative quantiﬁcation was used to determine the expression of
CCDC102B with respect to the expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as the reference. Stronger
CCDC102B expression was detected in the RPE-choroid than in
the retina (Fig. 2).
Association of myopic maculopathy with visual disturbance.
Visual prognosis was evaluated according to the maculopathy
grade in the 818 highly myopic patients from Kyoto University
Hospital. Patients were followed up for 51.7 ± 34.9 months, and
time course changes in visual acuity were assessed using the
Kaplan–Meier method. The eye with the more severe myopic
maculopathy grade at the initial visit was selected from right and
left eyes for the analysis, and the eye with poorer best corrected
visual acuity (BCVA) was used in patients with the same myopic
maculopathy grade in both eyes. According to International
Statistical Classiﬁcation of Diseases and Related Health Problems
10th Revision criteria, moderate visual impairment, severe visual
impairment, and blindness were deﬁned as 1/10 ≤ BCVA < 3/10,
1/20 ≤ BCVA < 1/10, and BCVA < 1/20, respectively. Low vision
included both moderate and severe visual impairment.
Figure 3 shows Kaplan–Meier curves of the time to lose 3/10, 1/
10, and 1/20 BCVA, with estimated overall survival rates of
57.9%, 73.1%, and 86·8% at 100 months. When survival analysis
was also performed for the two subgroups with and without
myopic maculopathy, eyes with myopic maculopathy had
signiﬁcantly lower retention rates (48.3% [<3/10], 67.0% [<1/
Table 1 Association of rs11873439 (chromosome 18, position 66744288) with myopic maculopathy in the Nagahama cohort
Stage N Effect allele EAF P OR (95% CI) Na Pa OR (95% CI)a
Control Case
Discovery 4476 C 0.418 0.529 1.46 × 10−10 1.56 (1.36–1.80) 4462 4.26 × 10−9 1.63 (1.38–1.92)
Replication 3279 C 0.440 0.505 4.20 × 10−4 1.30 (1.12–1.50) 3277 1.58 × 10−3 1.30 (1.11–1.53)
Meta-analysis 7755 C — — 1.77 × 10−12 1.43 (1.30–1.59) 7739 1.61 × 10−10 1·46 (1.30–1.64)
EAF effect allele frequency, OR odds ratio, CI conﬁdence interval
a Adjusted for age, sex, and axial length
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10], and 83.7% [<1/20] at 100 months) compared with eyes
without myopic maculopathy (96.8% [<3/10], 98.8% [<1/10], and
100% [<1/20] at 100 months; log-rank test P < 0.0001). These
results suggested that high myopia accompanying myopic
maculopathy was associated with an extremely poor visual
prognosis.
Discussion
Recent increases in the incidence of high myopia are expected to
lead to future increases in the rates of low vision and blindness
worldwide, although not all eyes with high myopia develop
vision-threatening complications. To date, it is not possible to
predict which eyes will suffer from vision-threatening complica-
tions of myopic maculopathy. Our GWAS using a Japanese
cohort showed that CCDC102B, encoding coiled-coil domain-
containing 102B, located at chromosome 18q22.1-q22.2, had a
genome-wide signiﬁcant association with myopic maculopathy.
Furthermore, an analysis of patients with high myopia revealed
that the CCDC102B locus was strongly associated with the
development of myopic maculopathy in highly myopic eyes, and
analyses with three ethnicities in Singapore supported this asso-
ciation. These ﬁndings, together with the higher rate of low vision
and blindness occurrence in eyes with myopic maculopathy
observed in the present study, suggested that CCDC102B likely
determines the fate of highly myopic eyes.
In this study, we provided clear evidence supporting the exis-
tence of a pathological difference between the phase of high
myopia induction and the phase of myopic maculopathy devel-
opment. Previous GWASs have discovered genes associated with
myopia as well as those associated with high myopia14–23.
However, CCDC102B was not included among the previously
reported myopia/high myopia susceptibility genes. Additionally,
in our GWAS cohort from Nagahama, CCDC102B rs11873439
did not show a signiﬁcant association with axial length, the most
important factor determining the myopic state of an eyeball. The
signiﬁcant association of CCDC102B with myopic maculopathy
development in highly myopic eyes, even after adjusting for axial
length, suggested that CCDC102B contributed to the stage of
developing myopic maculopathy rather than the stage of inducing
high myopia itself. Treatments targeting CCDC102B may thus
prevent the development of myopic maculopathy and blindness,
even after the occurrence of high myopia.
Although the effect of CCDC102B on myopic maculopathy was
replicated, the effect of CCDC102B was clearly attenuated in the
replication Japanese cohort as the odds ratio was 1.63 in the
discovery cohort albeit 1.30 in the replication cohort. Considering
that the odds ratio was 1.43 in the Nagahama cohort myopic
samples and 1.38 in the following case-control replication study
using hospital-based highly myopic samples, the initial effect size
in the discovery GWAS appeared to have been overestimated. In
our subgroup analysis, eyes with shorter axial length of 22–24
mm also showed odds ratio of 1.51. CCDC102B might affect the
development of maculopathy regardless of axial length and there
would be a threshold effect going from stage 1 to stage 2, but not
beyond stage 2.
In this study, we utilized East Asian populations to ﬁnd genetic
associations with myopic maculopathy development. Although
the incidence of high myopia is increasing for all ethnicities,
patients with myopic maculopathy are still common in East Asian
populations. We found that the C allele frequency of CCDC102B
rs11873439 in Indians was much lower than that in East Asians.
Furthermore, this C allele frequency was reportedly low, ~5%, in
Europeans. This result might explain the lower incidence of
myopic maculopathy in Caucasians. The best strategy to inves-
tigate preventive methods for high myopia-related blindness is
thus discovering genes associated with this complication in East
Asians, followed by animal experiments to elucidate the
mechanisms through which these complications develop; sub-
sequent application of the preventive method to other ethnicities
would then be indicated.









P OR (95% CI) Na Pa OR (95% CI)a
N EAF N EAF
Japanese Within Nagahama C 515 0.423 313 0.516 2.74 × 10−4 1.45 (1.19–1.78) 828 0.00358 1.43 (1.13–1.82)
Kyoto, Tokyo C 190 0.397 968 0.461 0.0221 1.29 (1.03–1.60) 1158 0.0205 1.38 (1.05–1.89)
Meta C 705 — 1281 — 2.70 × 10−5 1.38 (1.19–1.60) 1986 2.03 × 10−4 1.41 (1.18–1.69)
Chinese SCES C 134 0.369 41 0.488 0.0458 1.76 (1.01–3.07) 173 0.180 1.64 (0.795–3.40)
Maray SIMES C 35 0.386 36 0.444 0.448 1.32 (0.642–2.73) 71 0.713 0.851 (0.360–2.01)
Indian SINDI C 62 0.081 23 0.130 0.338 1.68 (0.580–4.88) 85 0.963 1.04 (0.22–4.84)
Meta 5 collections C 936 — 1381 — 2.40 × 10−6 1.40 (1.22–1.61) 2315 1.72 × 10−4 1.388 (1.17–1.65)
EAF effect allele frequency, OR odds ratio, CI conﬁdence interval
































Fig. 2 Expression of CCDC102B in the human retina and RPE-choroid.
CCDC102B expression in the human retina and human RPE-choroid
normalized to glyceraldehyde-3-phosphate dehydrogenase for cDNA
quantiﬁcation. Human retinal cDNA and RPE-choroid cDNA were obtained
from one individual, respectively, and the average of duplicate experiments
were used for qPCR analysis. RPE: retinal pigment epithelium. Error bars
show standard deviation
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Among the participants with high myopia in the Nagahama
cohort, 37.8% exhibited stage 2–4 myopic maculopathy. Com-
bined with our longitudinal study results on visual prognosis in
highly myopic eyes, 6.0% (0.378 × 0.16) of eyes will suffer from
blindness, and 19.7% (0.378 × 0.52) will suffer from low vision
within 10 years. As the prevalence of high myopia is now
increasing1–3, and myopic maculopathy continues to progress in
highly myopic eyes25, it is anticipated that more cases of low
vision and blindness will be encountered in the future.
Although the speciﬁc roles of CCDC102B have not been
reported in any organ to date, one group reported that a 2.7-Mb
deletion at chromosome 18q22.1 contributes to congenital dia-
phragmatic hernia with microphthalmia26,27. As this deletion can
interrupt CCDC102B, CCDC102B may affect both micro-
phthalmia and myopic maculopathy development in eyes. In
particular, congenital diaphragmatic hernia can develop through
damage to the muscle connective tissue, which contains an
abundance of collagen and elastin28. Notably, collagen and elastin
are the main constituents of Bruch’s membrane between the RPE
and choroid, where atrophy occurs in myopic maculopathy.
CCDC102B may thus contribute to the development of dia-
phragmatic hernia and myopic maculopathy by weakening con-
nective tissue.
Another possibility is that CCDC102B may affect actin-myosin
cytoskeletal structures. Among the CCDC family, the CCDC88A
protein has high homology to CCDC102B (BLASTP E value=
4.0 × 10−6). CCDC88A, also termed girdin, has important roles in
actin cytoskeleton integrity, retinal angiogenesis, and neurogen-
esis29–31. Moreover, non-muscle myosin II (NMMII) also has
high homology to CCDC102B; including non-muscle myosin
heavy chain IIB (NMMHCIIB, BLASTP E value= 4.0 × 10−9)
and non-muscle myosin heavy chain IIA (NMMHCIIA, BLASTP
E value= 2.0 × 10−8). Both NMMIIA and NMMIIB colocalize
with F-actin, and NMMHCIIB depletion reportedly reduces F-
actin levels in RPE cells32,33. The higher expression of CCDC102B
in the RPE-choroid as shown by our PCR results supports that
CCDC102B may promote atrophy of the RPE-choroid by weak-
ening cell integrity and cell adhesion in this tissue through
affecting actin-myosin cytoskeletal structures.
In conclusion, we identiﬁed a signiﬁcant association of
CCDC102B with the development of myopic maculopathy via two-
stage GWAS in a community-based cohort and case-control studies
using highly myopic patients. Because CCDC102B was not sig-
niﬁcantly associated with the occurrence of myopia, CCDC102B-
mediated mechanisms to develop myopic maculopathy may con-
stitute promising targets for the prevention of blindness, even after
the induction of high myopia. As many eyes with myopic macu-
lopathy will suffer from low vision and blindness in the future,
further studies on myopic maculopathy are warranted.
Methods
Study participants for the GWAS on myopic maculopathy grade. The study
population consisted of healthy Japanese volunteers enrolled in the Nagahama
Prospective Cohort for Comprehensive Human Bioscience (the Nagahama Study).
Participants were recruited between 2008 and 2010 from the general population of
Nagahama City in Japan16,34. Community residents ranging from 30 to 74 years of
age without physical impairment were eligible for this study. Blood sampling was
performed at the time of enrollment. Of the 9804 included participants, 14 with-
drew consent to participate and 26 were excluded because genetic analysis showed
an ethnic background other than Japanese.
All participants underwent ophthalmic examinations, including an objective
determination of the refractive error (Autorefractor ARK-530; Nidek, Gamagori,
Aichi, Japan), axial length measurements (IOLMaster; Carl Zeiss Meditec, Inc.,
Dublin, CA, USA), and color fundus imaging (CR-DG10; Canon, Tokyo, Japan).
Study participants comprised individuals with available DNA samples, fundus
imaging, and information regarding age and sex. Other exclusion criteria included
the presence of other macular-involving diseases, except for the fundus change
owing to myopia, such as age-related macular degeneration, retinal vein occlusion,
diabetic retinopathy, or retinitis pigmentosa. Subjects with poor quality fundus
images were also excluded.
The Kyoto University Graduate School and Faculty of Medicine Ethics
Committee and the Nagahama Municipal Review Board of Personal Information
Protection approved the study protocol and procedures used to obtain informed
consent. All study procedures were performed according to the tenets of the
Declaration of Helsinki. The purpose and procedures of the study were fully
disclosed to all participants, and each participant submitted written consent.
Analysis was performed after anonymization of patient records and information.
Genome-wide single-nucleotide polymorphism genotyping. Genomic DNA was
prepared from peripheral blood samples according to the manufacturer’s protocol.
Samples from 5299 participants who joined the Nagahama cohort from 2008 to

































Time from the first visit (months)
Myopic maculopathy (+)
Myopic maculopathy (–)
: Myopic maculopathy (+)



































Time from the first visit (months)
Myopic maculopathy (+)
Myopic maculopathy (–)
: Myopic maculopathy (+)

































Time from the first visit (months)
Myopic maculopathy (+)
Myopic maculopathy (–)
: Myopic maculopathy (+)
: Myopic maculopathy (–)
: All
Fig. 3 Kaplan–Meier survival analysis for visual acuity decline to low vision
and blindness among highly myopic patients according to myopic
maculopathy grade. Visual acuity decline to (a) 1/20, (b) 1/10, and (c) 3/10
was observed with a higher frequency in patients with myopic maculopathy
grades 2, 3, and 4 at baseline
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with HumanHap610 Quad (1830 samples), HumanOmni2.5-4 (1616 samples),
HumanOmni2.5-8 (378 samples), HumanOmni2.5 s (672 samples), CoreExome24
(1728 samples), and HumanExome (304 samples; Illumina, San Diego, CA, USA).
As a stringent quality control (QC), SNPs with a call rate of less than 99%,
minor allele frequency of less than 1%, and signiﬁcant deviation from
Hardy–Weinberg equilibrium (P < 1.0 × 10−6), and samples with a call rate of
<95% were excluded from the analysis. After this QC, 333 participants with
estimated ﬁrst- or second-degree kinship within Nagaham cohort samples (pi-hat
> 0.35, PLINK ver. 1.07 [http://zzz.bwh.harvard.edu/plink/]) were also excluded.
Genotype imputation was performed using MACH software (http://www.sph.
umich.edu/csg/abecasis/MACH/tour/imputation.html) with the 1000 genomes
dataset (phase3 v5 release) as a reference panel. Imputed SNPs for which R2 was
less than 0.5 were excluded from the following association analysis. Finally,
4,710,779 SNPs from 4476 individuals were used for the discovery stage analysis.
Of the 4476 samples, 14 lacked data of axial length.
Grading of myopic maculopathy in the Nagahama cohort. Two ophthalmolo-
gists, blinded to participant characteristics, performed grading of the fundus
photographs using the International Meta-Analysis for Pathologic Myopia
(META-PM) classiﬁcation system24. A senior retinal specialist adjudicated dis-
crepancies. When the grade differed in the right and left eyes, the eye with the more
severe META-PM classiﬁcation was selected for the analysis from each participant.
Replication for the association study on myopic maculopathy. To conduct a
replication study for the genetic association with myopic maculopathy, we geno-
typed the subset of remaining samples from the Nagahama Study (n= 3,421),
whose phenotypes were all available, using a commercially available assay (TaqMan
SNP assay with the ABI PRISM 7700 system; Applied Biosystems, Foster City, CA,
USA). Of these, 69 samples with poor fundus images, 55 samples without fundus
images in both eyes, and 18 samples of macular-involving diseases were also
excluded. Finally, 3279 samples were used for the replication stage analysis, of
which two samples lacked data of axial length.
Statistical analysis. Genome-wide case-control analysis was conducted for the
presence of myopic maculopathy in the discovery set of the Nagahama cohort.
Participants with myopic maculopathy grade 2, 3, or 4 in at least one eye were
considered cases, and participants with myopic maculopathy grade 0 or 1 in both
eyes were considered controls. For every post-QC SNP, we evaluated the associa-
tion between the genotypes and the presence or absence of pathologic myopic
maculopathy using logistic regression, assuming an additive model. This regression
framework allowed us to adjust for covariates such as age, sex, and axial length.
Experimental-wide signiﬁcance in the discovery stage was set at 1.06 × 10−8, cor-
responding to P= 0.05 divided by the 4,710,779 SNPs included in the analysis. All
meta-analyses were performed using a ﬁxed effect model. Differences were con-
sidered statistically signiﬁcant at P < 0.05 thereafter. Deviations in genotype dis-
tributions from the Hardy–Weinberg equilibrium were assessed using chi-square
tests. These statistical analyses were performed using R software (R Foundation for
Statistical Computing, Vienna, Austria; available at http://www.rproject.org/),
JMP® 12 (SAS Institute Inc., Cary, NC, USA), and PLINK software.
Association with myopic maculopathy in eyes with high myopia. Japanese
patients with high myopia were recruited from the Kyoto University Hospital (N=
818) and Tokyo Medical and Dental University Hospital (N= 340), excluding
patients with other ocular diseases such as retinal vein occlusion, diabetic retino-
pathy, severe glaucoma, or retinitis pigmentosa. High myopia was deﬁned as axial
length more than 26 mm in at least one eye. All procedures were performed
according to the tenets of the Declaration of Helsinki after approval of the pro-
tocols by the Institutional Review Board and the Ethics Committee of each par-
ticipating institute. The purpose and procedures of the study were fully disclosed to
all participants, and each patient submitted written consent.
Grading of the fundus photographs in both eyes was performed using the
META-PM classiﬁcation24. Genotypes of the 818 patients admitted at Kyoto
University Hospital were determined using TaqMan allelic discrimination probes
(Applied Biosystems). A series of BeadChip DNA arrays, namely HumanHap550
Quad (195 samples) and Human660W-Quad BeadChip (145 samples), were used
to determine the genotypes of patients in the Tokyo Medical and Dental University
Hospital, with the genotype of rs11873439 being directly determined by the chip.
We assessed long-term visual impairment from myopic maculopathy by
Kaplan–Meier estimates using the 818 patients with high myopia from Kyoto
University Hospital.
Association of CCDC102B in high myopia in other ethnicities. Participants with
high myopia were selected from the Singapore Chinese Eye Study (SCES), Singa-
pore Malay Eye Study (SiMES), and Singapore Indian Eye Study (SINDI); the
samples included 175 Chinese samples, 71 Malaysian samples, and 85 Indian
samples35,36. High myopia was deﬁned as SE of −5.0 D or less for the right eye, and
grading of the fundus photographs of right eye was performed using the META-
PM classiﬁcation. Age, sex, axial length in right eye, and principal components
were used as covariates in the logistic regression analysis. In the SCES cohort,
HumanHap610 Quad (132 samples) and Omniexpress chip (43 samples) were used
to determine the genotypes of rs11873439, and both the data were subjected to
meta-analysis. In both SiMES and SINDI cohorts, samples were genotyped using
the Illumina Human610 Quad Beadchip.
Quantitative real-time polymerase chain reaction. Human retinal cDNA and
RPE-choroid cDNA were obtained from ScienCell Research Laboratories (Carls-
bad, CA, USA) and BioChain Institute, Inc. (Newark, CA, USA). The SYBR Green
qPCR reaction mixture contained cDNA, forward primer, reverse primer, ROX
reference dye, and SYBR premix ExTaqTM II (TaKaRa Bio, Osaka, Japan). The
reactions in 96-well plates were performed using the Stratagene MX3000P real-
time PCR system (Santa Clara, CA, USA). The thermal cycle conditions were as
follows: 30 s at 95 °C, followed by 40 cycles at 95 °C for 5 s and 60 °C for 31 s.
Relative quantiﬁcation was used to determine the expression of CCDC102B. The
expression of GAPDH was used as the reference in the qPCR analyses.
The primer sequences were 5′-CTCTGCTCCTCCTGTTCGAC-3′ (forward)
and 5′-GCCCAATACGACCAAATCC-3′ (reverse) for GAPDH and 5′-TCATGG-
GCTACAATCTCATGCT-3′ (forward) and 5′-CGCAGGCGAAGTTCTTCAC-3′
(reverse) for CCDC102B. All reactions were performed in duplicate, and the
average values of experiments were used for analysis.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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